NCT01155960CompletedPhase 1
An Open Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two Period, Crossover, Single Dose Comparative Oral Bioavailability Study Of Anastrozole Tablets 1 mg (Test) Of Dr. Reddy's Laboratories Ltd., India And ARIMIDEX® Tablets 1 mg (Reference) Of Astrazeneca Pharmaceuticals LP, USA In Post Menopausal Healthy Women Subjects Under Fed Conditions.
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 36
- Primary Endpoint
- Bioavailability based on Cmax and AUC parameters
Study Overview
Brief Summary
The purpose of this study is to compare bioavailability in healthy, post menopausal women subjects under fed conditions.
Detailed Description
Open label, balanced, randomized, two treatment, two-sequence, two periods, crossover, single dose, comparative oral bioavailability study in healthy, post menopausal women subjects under fed conditions.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 37 Years to 67 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •The subjects should be postmenopausal healthy women who have attained complete menopause naturally or surgically and have not had menstruation for at least one year and are not on hormone replacement therapy.
- •The subjects should have Estradiol level ≤ 20 pg/ml & serum follicular stimulating hormone (FSH) level ≥ 50 mlU/ml during the screening.
- •The subjects should be screened within 21 days prior to the administration of first dose of the study drug.
- •The subjects should have a BMI between 18.5 to 26.4 (30-39 years), 18.5 to 27.8 (40-49 years), 18.5 to 28.4 (50-59 years) & 18.5 to 27.5 (60-69 years) weight in kg/ height2 in meter.
- •The subjects should be able to communicate effectively with study personnel.
- •The subjects should be able to give written informed consent to participate in the study.
Exclusion Criteria
- •The subjects who have a history of allergic responses to Anastrozole or other related drugs.
- •The subjects who are using female hormone replacement therapies, thyroid hormone replacement therapies, or antihypertensive therapies.
- •The subjects who have significant diseases or clinically significant abnormal findings during screening, (medical history, physical examination, laboratory evaluations, ECG, X-ray & lower abdominal ultrasonography recordings).
- •The subjects who have any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system.
- •The subjects who have a history or presence of bronchial asthma.
- •The subject who have used of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
- •The subjects who have history of drug dependence, recent history of alcoholism or of moderate alcohol use.
- •The subjects who are smokers, who smoke more than or equal to 10 cigarettes per day or more than or equal to 20 biddies per day or those who cannot refrain from smoking during study period.
- •The subjects with a history of difficulty with donating blood or difficulty in accessibility of veins.
- •The subjects who have donated (1 unit: 350 ml / 450 ml) blood within 90 days prior to receiving the first dose of study medication.
- •The subjects who have a positive hepatitis screen (includes subtypes A, B, C & E).
- •The subjects who have a positive test result for Human Immunodeficiency Virus (HIV) antibody and / or syphilis Rapid Plasma Reagin, Venereal Disease Research Laboratory (RPR/VDRL).
- •The subject who received an investigational product, or has participated in a drug research study within a period of 90 days prior to the first dose of the study medication administration.
Arms & Interventions
Arimidex
Active Comparator
Arimidex® Tablets 1 mg
Intervention: Anastrozole (Drug)
Anastrozole
Experimental
Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
Intervention: Anastrozole (Drug)
Outcomes
Primary Outcomes
Bioavailability based on Cmax and AUC parameters
Time Frame: 3 Months
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Completed
Phase 1
Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting ConditionsHealthyNCT01155947Dr. Reddy's Laboratories Limited36
Completed
Phase 1
Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting ConditionsHealthyNCT01375452Dr. Reddy's Laboratories Limited36
Completed
Phase 1
Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed ConditionsHealthyNCT01372982Dr. Reddy's Laboratories Limited36
Completed
Phase 1
A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With ItraconazoleHealthy SubjectsNCT05551897AstraZeneca14
Completed
Phase 1
Three-way Crossover Study Comparing Ondansetron ODFS Administered With and Without Water to Zofran ODT Without WaterHealthy ParticipantsNCT01220167Aquestive Therapeutics18